Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0952W HIGH $7.82
Volume
728.22 K
Value Traded
1.84 M
Short % Float
5.95%
Days to Cover
2.9
+0.8%Week
+5.42%1 Month
-36.43%3 Month
-45%6 Month
-48.16%5 Year
-98.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
149.51 M
EPS (TTM)
-1.27
P/E Ratio
-
Ent. Value
6.43 M
Total Shares
59.10 M
Float Shares
54.38 M
Insiders
11.68%
Institutions
66.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TARA Catalyst Timeline
Dated clinical, regulatory and corporate events for Protara Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Protara Therapeutics, Inc.
276Total events
8Upcoming
44Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseTARA-002FiledCorporate
Asset purchase agreement with Novex Innovations for TARA-002 manufacturing-related assets ($8.75M)
▲Enrollment CompleteTrial
Enrollment completed in Phase 2b dose confirmation phase of THRIVE-3
intestinal failure with choline deficiency in patients dependent on parenteral supportsource ↗
◆Trial InitiationTARA-002FiledTrial
Initiation of ADVANCED-3 registrational trial
BCG-Naïve and BCG-Exposed NMIBCsource ↗
▲Enrollment CompleteTrial
Completed enrollment of Phase 2b portion of THRIVE-3
Choline deficiency in patients dependent on parenteral supportsource ↗
◆Oral PresentationPresentation
Protara management to present at TD Cowen 7th Annual Oncology Innovation Summit
◆Poster PresentationTARA-002FiledPresentation
Interim safety and durability data from STARBORN-1 at ISSVA 2026
Lymphatic Malformationssource ↗
◆Oral PresentationTARA-002FiledPresentation
Virtual investor webinar on TARA-002 in LMs with KOL
Lymphatic Malformationssource ↗
◆Poster PresentationTARA-002FiledPresentation
Encore poster presentation of previously reported data from Cohort B of ADVANCED-2 trial at AUA 2026
BCG-Unresponsive non-muscle invasive bladder cancersource ↗
▲Enrollment CompleteTARA-002FiledTrial
Enrollment completed in BCG-Naïve cohort of ADVANCED-2
BCG-Naïve NMIBCsource ↗
◆Enrollment CompleteTARA-002FiledTrial
Enrollment completion expected in BCG-Unresponsive cohort of ADVANCED-2
BCG-Unresponsive NMIBCsource ↗
◆Trial InitiationTARA-002FiledTrial
Initiate ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026
Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
▲Interim AnalysisTARA-002FiledTrial
Interim data from ADVANCED-2 trial showed 68% complete response rate at six months in BCG-Unresponsive patients
non-muscle invasive bladder cancer (NMIBC)source ↗
▲Breakthrough Therapy DesignationTARA-002FiledDesignation
Breakthrough Therapy designation granted by FDA for TARA-002 in LMs
lymphatic malformations (LMs)source ↗
▲Fast Track DesignationTARA-002FiledDesignation
Fast Track designation granted by FDA for TARA-002 in LMs
lymphatic malformations (LMs)source ↗
▼Equity OfferingCorporate
Oversubscribed $86 million public offering with participation from new and existing investors
◆Poster PresentationTARA-002FiledPresentation
Poster presentation of updated interim efficacy and safety data from BCG-Unresponsive NMIBC cohort at ASCO GU 2026
BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC)source ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference fireside chat
▲Enrollment CompleteTARA-002FiledTrial
Enrollment completed in BCG-Naïve cohort of ADVANCED-2
Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
◆Oral PresentationPresentation
Protara Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference
▲Breakthrough Therapy DesignationTARA-002FiledDesignation
Breakthrough Therapy designation granted for TARA-002 in LMs
lymphatic malformationssource ↗
▲Fast Track DesignationTARA-002FiledDesignation
Fast Track designation granted for TARA-002 in LMs
lymphatic malformationssource ↗
▲First Patient DosedTrial
First patient dosed in THRIVE-3 registrational trial of IV Choline Chloride
patients dependent on long-term parenteral supportsource ↗
●Manufacturing MilestoneTARA-002FiledCMC / Inspection
TARA-002 selected for FDA CMC Development and Readiness Pilot (CDRP) Program
▲First Patient DosedTrial
First patient dosed in Phase 3 registrational THRIVE-3 trial of IV Choline Chloride
patients receiving long-term parenteral supportsource ↗
▲Breakthrough Therapy DesignationTARA-002FiledDesignation
FDA granted Breakthrough Therapy designation for TARA-002 in pediatric LMs
pediatric patients with macrocystic and mixed cystic lymphatic malformationssource ↗
▲Fast Track DesignationTARA-002FiledDesignation
FDA granted Fast Track designation for TARA-002 in pediatric LMs
pediatric patients with macrocystic and mixed cystic lymphatic malformationssource ↗
▲Manufacturing MilestoneTARA-002FiledCMC / Inspection
TARA-002 selected for FDA CMC Development and Readiness Pilot (CDRP) Program
lymphatic malformations and non-muscle invasive bladder cancersource ↗
◆FDA Feedback ReceivedTARA-002FiledFDA Meeting
Regulatory update expected in 1H 2026 for TARA-002 in LMs
lymphatic malformations (LMs)source ↗
◆Interim AnalysisTARA-002FiledTrial
Interim results from approximately 25 BCG-Unresponsive patients in ADVANCED-2 trial
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Topline ReadoutTARA-002FiledClinical Data
Interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial
BCG-Unresponsive NMIBCsource ↗
▼Equity OfferingCorporate
Closing of $75 million underwritten public offering of common stock
▼Equity OfferingCorporate
Protara announces proposed public offering of $75 million common stock and pre-funded warrants
◆Poster PresentationTARA-002FiledPresentation
Poster presentation of interim data from Cohort A of ADVANCED-2 trial at SUO 2025
BCG-Naïve non-muscle invasive bladder cancer (NMIBC)source ↗
▲Poster PresentationTARA-002FiledPresentation
Updated interim data presented at SUO 2025
BCG-Naïve NMIBCsource ↗
▲FDA Feedback ReceivedTARA-002FiledFDA Meeting
FDA written feedback supporting registrational design for controlled trial in BCG-Naïve patients
BCG-Naïve NMIBCsource ↗
◆Oral PresentationTARA-002FiledPresentation
Interim Data Presentation From the ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at SUO Annual Meeting
BCG-naive NMIBCsource ↗
▲Topline ReadoutTARA-002FiledClinical Data
Positive interim results in BCG-Naïve NMIBC patients reported at SUO
BCG-Naïve NMIBCsource ↗
▲Interim AnalysisTARA-002FiledTrial
Positive interim results from Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations
lymphatic malformationssource ↗
◆Oral PresentationTARA-002FiledPresentation
Conference call and webcast to review new interim data from Phase 2 STARBORN-1 trial
lymphatic malformationssource ↗
◆Topline ReadoutTARA-002FiledClinical Data
Interim update with results from approximately 25 six-month evaluable BCG-Unresponsive patients
Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
◆Interim AnalysisTARA-002FiledTrial
Interim update from STARBORN-1 trial in pediatric patients with LMs
lymphatic malformations (LMs)source ↗
▲First Patient DosedTrial
First patient dosed in registrational THRIVE-3 trial of IV Choline Chloride
patients on parenteral support (PS)source ↗
Past FDA Catalysts and PDUFA Decisions
How TARA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-15 | TARA-002 | Phase 2 interim results | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Micro Cap(rank 179 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Choline Chloride Enzyme Replacement Therapies (ERT)NCT06910943 | Choline Deficiency | Phase 2/3 | RECRUITING | 129 | Jan 1, 2029 | ||||||
| TARA-002 Cell TherapiesNCT07480356 | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | RECRUITING | 284 | Nov 1, 2032 | ||||||
| TARA-002 Cell TherapiesNCT05871970 | Lymphatic Malformation | Phase 2 | RECRUITING | 38 | May 1, 2027 | ||||||
| TARA-002 Cell TherapiesNCT05085977 | Non-muscle Invasive Bladder Cancer | Phase 2 | COMPLETED | 153 | Oct 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every TARA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TARA-002 BreakthroughFast TrackOrphan+1 | non-muscle invasive bladder cancer (NMIBC) | Phase 2 | 2026-05-15 | complete response rate any time: 72.4%; complete response rate 6 months: 66.7%; complete response rate 12 months: 55.0%; maintaining cr probability 6 months: 73.1%; maintaining cr 9 to 12 months: 91.7%; re induced patients cr 6 months: 66.7%Read More | Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shefferman JesseDirector, Officer (CEO and President) | Disposition | -14,000 707,832 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TARA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.2 % | 8.48 M | 2.22 M | 187.35% ( 1.45 M) |
Ownership Trends
TARA Short Interest
Shares sold short, counted twice a month.
5.95%
Short % of Float
of tradable shares sold short
3.2M
Shares Sold Short
-46.9% vs prior count
2.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TARA ranks across every disease it competes in
Competitive Position is a premium feature
See how TARA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTARA News
TARA▲ +8%on this news· ran to +23% by day 3
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics reported its third quarter 2026 financial results, highlighting progress in clinical trials for TARA-002. The company expects to complete enrollment in the ADVANCED-2 trial for NMIBC by year-end 2026 and the STARBORN-1 trial for LMs in early 2027. Additionally, Protara has secured $143 million in cash to support operations through 2028.
Read more →TARAProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics has completed enrollment for the Phase 2b open-label dose confirmation phase of the THRIVE-3 trial, evaluating IV Choline Chloride in patients with intestinal failure. The trial aims to address the significant choline deficiency in patients on parenteral support. Interim results are expected in Q4 2026, with the potential for IV Choline Chloride to become the first FDA-approved formulation for this patient group.
Read more →TARAProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Protara Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company focuses on developing therapies for cancer and rare diseases, including its lead candidate, TARA-002. This investigational therapy is currently in clinical trials for non-muscle invasive bladder cancer and lymphatic malformations.
Read more →TARAProtara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics reported a second quarter net loss of $21.7 million, or $0.36 per share. The company held approximately $162 million in cash and investments as of June 30, 2026. Management expects to complete enrollment in the ADVANCED-2 trial and report interim results from the THRIVE-3 trial in the fourth quarter of 2026. The firm plans to submit a Biologics License Application for TARA-002 in the second half of 2027.
Read more →TARA▲ +9.7%on this news
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Protara Therapeutics will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026. The event will provide insights related to ASCO and EHA. Protara is focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002, which is in Phase 2 trials.
Read more →TARA▼ -9.8%on this newsshared move
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Protara Therapeutics, Inc. will host a virtual webinar on May 19, 2026, to discuss its investigational therapy TARA-002 for Lymphatic Malformations. The event will cover the treatment landscape, expert opinions, and clinical data supporting TARA-002's use. TARA-002, which has received several FDA designations, is a first-in-class therapy aimed at enhancing immune response through the activation of critical immune pathways. Lymphatic Malformations are rare conditions that currently lack approved treatments.
Read more →TARAProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics has announced positive 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The treatment demonstrated a 72% complete response rate at any time and a favorable safety profile. The company plans to initiate the ADVANCED-3 trial in the second half of 2026, further evaluating TARA-002's efficacy.
Read more →TARAProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics announced its Q1 2026 financial results and provided updates on its clinical programs. The company plans to submit a Biologics License Application for TARA-002 in Lymphatic Malformations by the second half of 2027. Protara also aims to complete enrollment in the ADVANCED-2 trial and initiate the ADVANCED-3 trial for non-muscle invasive bladder cancer in 2H 2026. The company reported a net loss of $17.8 million for the quarter but maintains strong cash reserves.
Read more →TARAProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
Protara Therapeutics announced it will present updated interim data from the Phase 2 ADVANCED-2 trial of TARA-002 for BCG-Naïve NMIBC patients at the AUA 2026 Annual Meeting. The presentation will include new safety and efficacy data from 31 patients, alongside previously reported data for BCG-Unresponsive patients. TARA-002 is a first-in-class therapy showing promise in treating non-muscle invasive bladder cancer.
Read more →TARAProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Protara Therapeutics has announced its fourth quarter and full year 2025 financial results alongside positive interim data from the ADVANCED-2 trial for its lead candidate, TARA-002, in non-muscle invasive bladder cancer (NMIBC). The drug achieved a 68% complete response rate at six months in patients unresponsive to previous treatment. Additionally, the company anticipates completing enrollment for its registrational cohort in 2026, along with plans for a new trial. Protara is well funded, with $198 million available to continue its developmental program into 2028.
Read more →TARA▼ -26.4%on this news
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protara Therapeutics announced promising interim results from the Phase 2 ADVANCED-2 trial of TARA-002 for treating BCG-unresponsive non-muscle invasive bladder cancer. The therapy achieved a 68% complete response rate at six months, with no severe adverse events reported. The company plans to complete enrollment for the trial's BCG-unresponsive cohort by the second half of 2026.
Read more →TARA▲ +7.2%on this news· ran to -18% by day 3shared move
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. At these conferences, management will engage in fireside chats to discuss the company's initiatives and progress. Protara is dedicated to developing innovative therapies for cancer and rare diseases, with TARA-002 currently in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations.
Read more →TARAProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
Protara Therapeutics, Inc. has announced the grant of inducement stock options and restricted stock units to a newly-hired employee. The grants include 10,200 stock options and 5,100 RSUs, with vesting schedules tied to the employee's continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent as it develops therapies for cancer and rare diseases.
Read more →TARAProtara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Protara Therapeutics will present updated interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for BCG-Unresponsive NMIBC patients at the ASCO Genitourinary Cancers Symposium. The presentation will include safety and efficacy data from approximately 25 evaluable patients. TARA-002 is a novel investigational therapy aimed at treating non-muscle invasive bladder cancer.
Read more →TARA▼ -8.9%on this news
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Protara Therapeutics has announced significant updates and milestones for 2026, focusing on its investigational therapies for cancer and rare diseases. The company plans to report interim results for its ADVANCED-2 trial and has received FDA designations for TARA-002 in lymphatic malformations. In addition, Protara has dosed the first patient in the THRIVE-3 trial evaluating IV Choline Chloride, aiming to assist patients on parenteral nutrition. A recent public offering has further solidified the company's financial position, extending its cash runway into 2028.
Read more →TARA▲ +11.1%on this newsshared move
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Protara Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations. A live webcast of the presentation will be available on their website.
Read more →TARA▲ +11.1%on this newsshared move
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Protara Therapeutics has commenced patient dosing in its Phase 3 THRIVE-3 trial, evaluating IV Choline Chloride for patients on long-term parenteral support. This investigational therapy aims to address choline deficiency, which affects a significant percentage of this patient population. The trial follows an earlier Phase 2b study and aims to provide interim results in late 2026.
Read more →TARAProtara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics announced that the FDA has granted Breakthrough Therapy and Fast Track designations for TARA-002, an investigational therapy for pediatric patients with lymphatic malformations. This recognition highlights the urgent need for effective treatments in this area. Additionally, TARA-002 has been selected for the CMC Development and Readiness Pilot Program, facilitating its development process.
Read more →TARAProtara Announces Closing of $75 Million Public Offering
Protara Therapeutics, Inc. has concluded a public offering of 13,043,479 shares at a price of $5.75 per share, raising approximately $75 million. The proceeds will be utilized primarily for the clinical development of TARA-002 and several other clinical programs. Additionally, the company has given underwriters a 30-day option to purchase up to 1,956,521 additional shares. This offering was part of an effective shelf registration statement and demonstrates strong interest from investors.
Read more →TARA▼ -18.8%on this newsshared move
Protara Announces Pricing of $75 Million Public Offering
Protara Therapeutics has announced the pricing of a public offering of 13,043,479 shares at $5.75 each, aiming to raise approximately $75 million. The offering is expected to close on December 8, 2025, and the funds will support the clinical development of TARA-002 and other programs. The company has granted underwriters a 30-day option to purchase additional shares.
Read more →About Protara Therapeutics, Inc.
Headquarters345 PARK AVENUE SOUTH, NEW YORK, NY, 10010
BIOPHARMAWATCH ELITE
Trade the next TARA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime